BioSpace News Archive

Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.

CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas Seshadri, Ph.D., M.B.A., as Senior Vice President, Head of Research & Clinical Development, effective June 1, 2021.

Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that Dr. Adaeze Enekwechi will join the firm in June as an Operating Partner.

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM). Novocure’s TTFields are electric fields that disrupt cancer cell division.

ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced it has appointed Paul M. Peloso , MD, a

- Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilisation (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at week 26 - Mean haemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019)

Universe Pharmaceuticals INC, a pharmaceutical producer and distributor in China, announced that the Company entered into a letter of intent on April 23, 2021 for strategic cooperation with Kitanihon Pharmaceutical Co., Ltd., a Japanese company engaged in the research, development, manufacturing, and distribution of pharmaceutical and medical products.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that its management team will be presenting at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021.